SEC Form 4 · accession 0001104659-17-048996
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carrie L. Bourdow
Officer — Director
Period of report
Jul 31, 2017
Accepted (ET)
Aug 2, 2017 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Jul 31, 2017 | A | 20,200 | A | — | Jul 31, 2027 | Ordinary Shares | 20,200 | 20,200 | D |
Explanation of responses
- F1The exercise price is Euro 8.94 per share.
- F2This option was granted on July 31, 2017. Vesting began on July 31, 2017 and ends on July 31, 2020. This option vests on a monthly pro-rata basis at the end of each successive month following July 31, 2017.